Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377290 | 0.96 | CYP19A1 (0.62) | CYP19A1NPC1RAB9ABCHEPTGS2 | |
| SCHEMBL11965518 | 0.83 | FLT3 (0.46) | CYP19A1NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL23381117 | 0.82 | CYP19A1 (0.43) | CYP19A1CA2CA9 | |
| SCHEMBL9729950 | 0.81 | PTGS2 (0.46) | CYP19A1NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL12377326 | 0.81 | PTGS2 (0.46) | CYP19A1NPC1RAB9APTGS2PTGS1 | |
| SCHEMBL25825570 | 0.81 | CYP19A1 (0.49) | CYP19A1NPC1RAB9ALMNACA2 | |
| SCHEMBL19449445 | 0.81 | MIF (0.51) | CYP19A1LMNASMN1; SMN2KDREPHB4 | |
| SCHEMBL19697583 | 0.81 | CA2 (0.48) | CYP19A1NPC1RAB9ATSHRCA12 | |
| SCHEMBL25898935 | 0.80 | CYP19A1 (0.47) | CYP19A1NPC1RAB9ALMNACA2 | |
| SCHEMBL22050888 | 0.80 | CHRNB2 (0.46) | CYP19A1CA12CA9KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718600-B2 | 1,2,3-triazole inhibitors of P97 AAA ATPase activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-08-08 | — | — | US | disclosed |
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2021222767-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11130764-B2 | Analogs of vincamine and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-10028938-B2 | Antiviral agents and uses thereof | GRIFFITH UNIVERSITY (AU) | 2018-07-24 | — | — | US | disclosed |
| US-10028938-B2 | Antiviral agents and uses thereof | GRIFFITH UNIVERSITY (AU) | 2018-07-24 | — | — | US | disclosed |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2017-10-12 | — | — | US | disclosed |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2017-10-12 | — | — | US | disclosed |
| US-20130274212-A1 | Sesterterpene Compounds and Use Thereof | SNU R&DB FOUNDATION (KR) | 2013-10-17 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | CYP19A1 2015/4885NPC1 3086/4885RAB9A 809/4885 |
| US-11718600-B2 | 1,2,3-triazole inhibitors of P97 AAA ATPase activity | ATAD3B, ATAD3A, PSMG3 | CYP19A1 3861/4885NPC1 399/4885RAB9A 1405/4885 |
| US-20210047293-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY13 | CYP19A1 2015/4885NPC1 3086/4885RAB9A 809/4885 |
| US-20170290809-A1 | ANTIVIRAL AGENTS AND USES THEREOF | RNASE1, ENTPD5, ACE | CYP19A1 4529/4885NPC1 1326/4885RAB9A 1505/4885 |
| US-10028938-B2 | Antiviral agents and uses thereof | RNASE1, ENTPD5, ACE | CYP19A1 4529/4885NPC1 1326/4885RAB9A 1505/4885 |
| US-20130274212-A1 | Sesterterpene Compounds and Use Thereof | LIPC, LIPE, FABP4 | CYP19A1 814/4885NPC1 458/4885RAB9A 2494/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CYP19A1 2334/4885NPC1 1934/4885RAB9A 1162/4885 |
| US-11130764-B2 | Analogs of vincamine and uses thereof | GLS, GLS2, VAT1 | CYP19A1 209/4885NPC1 3456/4885RAB9A 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.